COAG Hemab Therapeutics Holdings, Inc. Insider Trading

RA Capital Management (10% owner) purchases 67,669 shares at avg $24.97 across 2 transactions, holding 6,444,637 shares post-transaction

RA Capital Management executed two separate purchases totaling 67,669 shares for $1,689,818.48 on 2026-06-15 and 2026-06-16, increasing its position by 1.1% to 6,444,637 shares. This builds on a consistent pattern: all 5 prior purchases at COAG were well-timed at the 90-day mark, with positive cumulative returns of +2.2% to +4.4%. The stock currently trades at $26.45, above the blended transaction price of $24.97 but -27.8% from its 52-week high of $36.61, and the company is operating at a net loss of $-22,687,000.00 with a market cap of $1,235,358,094.50. The consistent accumulation alongside a 100% track record at this specific ticker suggests methodical conviction, though the macro position (negative earnings, significant distance from highs) warrants close attention to whether the insider's prior success at COAG continues.

RA Capital Management (10% owner) purchased 4,798 shares at $24.96 avg across 2 transactions, bringing holdings to 6,376,968 shares

RA Capital Management executed 2 separate purchases totaling 4,798 shares for $119,776.18 on May 19–20, 2026, at an average price of $24.96. The transaction increased its stake from 6,372,170 shares to 6,376,968 shares, representing a net change of purchased 4,798 shares. Given Hemab's recent listing (14 trading days), the current price of $26.30 reflects early-stage market discovery. The modest incremental purchase and the minimal percentage increase in holdings suggest a measured approach rather than a concentrated accumulation event.

RA Capital Management bought 6,387 shares of COAG at $24.90, adding $159,036.30 to a 6.37M-share position in a recently listed stock.

RA Capital Management, LP, a 10% owner of Hemab Therapeutics Holdings, Inc. (COAG), purchased 6,387 shares at $24.90, bringing its total holding to 6,372,170 shares. The stock is in its early trading life with only 9 trading days since listing, and the current price of $28.37 sits above the transaction price, suggesting the position is in the money relative to this purchase. While the incremental dollar value of $159,036.30 is modest relative to the firm's existing 6.37M-share stake, the continued accumulation by a major 10% owner shortly after listing is a notable signal of sustained institutional commitment. Investors should monitor whether RA Capital continues to add to its position as the company establishes its post-listing trading history.

Ra Capital Management (10% owner) acquired 51,258 shares across five open-market purchases at newly public COAG, its 79th open-market purchase in 36 months.

Ra Capital Management, a substantial institutional holder, spent approximately $1.27 million to acquire over 51,000 shares of Hemab Therapeutics across five trades, each priced just above or below the newly-public stock's listing reference point. While the stock has traded below its 52-week high since IPO, this represents typical portfolio activity for a fund rather than insider conviction—Ra Capital's extensive filing history shows 79 open-market purchases over the past three years alongside 92 open-market sales, reflecting active portfolio management rather than directional betting on the company. The purchases do occur at a point where the stock has pulled back from its post-IPO highs, aligning with the historical pattern that when Ra Capital has been a net buyer in prior transactions, subsequent returns have been positive over longer horizons. However, this is institutional rebalancing activity, not a signal of executive or board-level confidence in COAG's prospects.

Ra Capital Management, 10% owner and director, deployed substantial capital across multiple open-market purchases at Hemab Therapeutics (COAG).

L.P. Ra Capital Management, a director and significant institutional shareholder, executed a series of open-market purchases totaling approximately $52.2 million across three trading days, adding nearly 2.9 million shares to its position. The timing coincides with the stock trading at its lowest point in its brief public history, suggesting the fund saw a tactical opportunity despite the steep discount from recent highs. Ra Capital's track record shows a strong history with prior purchases — all completed within the past 90 days have been profitable, indicating disciplined entry timing. This purchase represents a substantial reaffirmation of confidence in Hemab's prospects: Ra Capital is not a passive holder but an active accumulator willing to deploy significant capital when valuations compress. The scale and conviction of this institutional accumulation warrant monitoring as a potential signal that sophisticated capital sees value below current prices.